Risk factors

Geron (GERN) risk factors

Item 1A of every Geron Corp. 10-K on file, and what changed from one year to the next.

Open GERN in Gloomberb →
  • FY2025 10-K risk factors

    60 risks, 20 new, 14 dropped, 26 reworded since the prior year. RYTELO is now approved in the EU, adding EU commercialization, reimbursement, orphan-exclusivity, and regulatory risks.

    Filed Mar 02, 2026
  • FY2024 10-K risk factors

    74 risks. Geron is a commercial-stage biopharmaceutical company wholly dependent on the success of its sole approved product, RYTELO (imetelstat). The company faces major risks regarding sales execution, manufacturing supply chains, reimbursement, and heavy indebtedness under its Pharmakon loan.

    Filed Feb 27, 2025